USANA EPS Estimate Up 5.3% to $2.00 While Shares Slide 40.8%
Analysts have raised USANA’s 2026 EPS forecast by 5.3% to $2.00 over the past 60 days, reflecting upward revisions from sustained earnings-beat performance. The company holds a Zacks Rank #1 Strong Buy despite a 40.8% decline in shares over the past six months.
1. EPS Revision and Outlook
Analysts have increased USANA’s projected 2026 EPS from $1.90 to $2.00 over the last 60 days, reflecting growing confidence in revenue growth and margin expansion. The upward revision underscores improved expectations for the company’s core nutritional supplement business.
2. Share Performance Decline
USANA’s shares have declined 40.8% over the past six months amid broader biotech volatility and investor rotation. The steep drop positions the stock as attractively valued against its improved earnings forecast.
3. Zacks Ranking and Earnings Beat Track Record
USANA holds a Zacks Rank #1 Strong Buy, driven by three out of four consecutive quarterly earnings beats. The average surprise of 21.92% highlights management’s ability to outperform guidance.